BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...compound #), axitinib (Generic), Inlyta (Other) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) Pexa-Vec, pexastimogene devacirepvec (TG6006, JX-5940TG6006, JX-594) ZKAB001 (STI-A1014) Amgen...
BioCentury | Oct 6, 2014
Company News

Sorrento, Lee's Pharmaceutical deal

...Sorrento granted Lee's Pharmaceutical exclusive rights to develop and commercialize Sorrento's STI-A1014 in Taiwan and China...
BioCentury | Oct 4, 2014
Company News

Lee's gets China rights to Sorrento's anti-PD-L1

...Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) obtained exclusive rights to STI-A1014 human mAb against PD-L1 in greater...
...greater China, including mainland China, Hong Kong, Macau and Taiwan from Sorrento Therapeutics Inc. (NASDAQ:SRNE). STI-A1014...
Items per page:
1 - 3 of 3